Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

37.28USD
26 May 2017
Change (% chg)

$-0.26 (-0.69%)
Prev Close
$37.54
Open
$37.66
Day's High
$37.66
Day's Low
$37.03
Volume
58,566
Avg. Vol
62,713
52-wk High
$54.70
52-wk Low
$37.03

Select another date:

Thu, May 25 2017

BRIEF-Dr.Reddy's Labs' audit of formulations Srikakulum plant Unit II completed with zero observations

* Says audit of formulations Srikakulum Plant unit II, Andhra Pradesh by US FDA, completed with zero observations. Source text - (http://bit.ly/2qnkt2M) Further company coverage:

BRIEF-Dr.Reddy's Laboratories says USFDA approved launch of doxorubicin hydrochloride liposome injection in U.S.

* Announces USFDA approval for launch of doxorubicin hydrochloride liposome injection in U.S. Market Source text - (http://bit.ly/2qQ6RC6) Further company coverage:

BRIEF-India's Dr.Reddy's Laboratories March-qtr consol profit rises about three-fold

* Consensus forecast for March quarter consol profit was 4.27 billion rupees

BRIEF-Dr. Reddy's Labs launches Ezetimibe and Simvastatin tablets in U.S. market

* Says launch of Ezetimibe and Simvastatin tablets in U.S. market Source text for Eikon: Further company coverage:

BRIEF-Fresenius sees no change in relationship of Merck KGaA's unit with partner Dr Reddy's

* Fresenius ceo sturm says we've had a good q1 but will not provide details

BRIEF-Dr.Reddy's Laboratories announces launch of progesterone capsules in the U.S.

* Dr.Reddy's Laboratories - announces the launch ofprogesterone capsules in the U.S. market". Source text: (http://bit.ly/2pLTt0P) Further company coverage:

Judge tosses drug packaging case against Dr. Reddy's, pharmacies

Dr. Reddy's Laboratories Ltd and three pharmacy chains have won the dismissal of a whistleblower lawsuit accusing them of fraudulently seeking federal reimbursement for drugs that were distributed in packaging not tested for child safety.

BRIEF-Dr. Reddy's Labs, Integra Lifesciences sign deal to market Duragen products in India

* Co, Integra Lifesciences enter agreement to market, distribute Duragen plus and suturable duragen dural regeneration in India

BRIEF-Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories

* Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market

BRIEF-Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant

* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017

Select another date:

More From Around the Web